Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > RDW on youtube posted today
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(631)
•••
Comment by 99942Apophison Dec 02, 2023 11:31am
242 Views
Post# 35765095

RE:RE:RE:RE:RE:RE:RDW on youtube posted today

RE:RE:RE:RE:RE:RE:RDW on youtube posted today
Mikee3003 wrote: No that was not a mistake, he said 2026 and he meant it!



Once again correct if wrong, thank you. When Roger said 2026 was that to treat the patient population over & above the 30 to 40 percent of unresponsive NMIBC? 
Ok what I'm saying here is if they get AA & BTD then can they not immediately treat the unresponsive population and after PH2 is completed and have reached 15 or 18 months on all patients, Theralase should be able to demonstrate higher efficacy, durability and with less AE's and less treatments. This would take them into 2026 which would be the point Roger spoke of and would be the balance or 60 to 70 percent remaining of NMIBC cases.
Remember a CEO can't assume AA or BTD so when any CEO discusses future possibilities they must look at point of completion without early approval.  
All in my opinion and please correct or criticize, thanks.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities